Literature DB >> 14504074

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.

David Marin, John M Goldman, Eduardo Olavarria, Jane F Apperley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14504074     DOI： 10.1182/blood-2003-06-2042

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

Review 1.  Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Authors:  Hagop Kantarjian; Susan O'Brien; Jorge Cortes; William Wierda; Stefan Faderl; Guillermo Garcia-Manero; Jean-Pierre Issa; Elihu Estey; Michael Keating; Emil J Freireich
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

2.  NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

Authors:  Susan O'Brien; Ellin Berman; Joseph O Moore; Javier Pinilla-Ibarz; Jerald P Radich; Paul J Shami; B Douglas Smith; David S Snyder; Hema M Sundar; Moshe Talpaz; Meir Wetzler
Journal:  J Natl Compr Canc Netw       Date:  2011-02       Impact factor: 11.908

3.  Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report.

Authors:  Hadi Alphonse Goubran
Journal:  J Med Case Rep       Date:  2009-04-29

4.  Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Onco Targets Ther       Date:  2008-10-01       Impact factor: 4.147

5.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

Authors:  Hagop Kantarjian; Ricardo Pasquini; Vincent Lévy; Saengsuree Jootar; Jerzy Holowiecki; Nelson Hamerschlak; Timothy Hughes; Eric Bleickardt; David Dejardin; Jorge Cortes; Neil P Shah
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

6.  Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.

Authors:  Hagop M Kantarjian; Richard A Larson; Francois Guilhot; Stephen G O'Brien; Manisha Mone; Marc Rudoltz; Tillmann Krahnke; Jorge Cortes; Brian J Druker
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

7.  Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

Authors:  Elias Jabbour; Hagop M Kantarjian; Dan Jones; Jenny Shan; Susan O'Brien; Neeli Reddy; William G Wierda; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Journal:  Blood       Date:  2008-12-05       Impact factor: 22.113

Review 8.  Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.

Authors:  Elias Jabbour; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

Review 9.  Treatment selection after imatinib resistance in chronic myeloid leukemia.

Authors:  Elias Jabbour; Jorge Cortes; Hagop Kantarjian
Journal:  Target Oncol       Date:  2009-01-30       Impact factor: 4.493

Review 10.  Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

Authors:  Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.